创新药再迎政策东风 16条新举措含金量高

Core Insights - The National Healthcare Security Administration (NHSA) and the National Health Commission have introduced measures to support the high-quality development of innovative drugs in China, focusing on five key areas with 16 specific initiatives aimed at enhancing the R&D and accessibility of innovative drugs [1][2] Group 1: Policy Measures - The measures emphasize strengthening support for innovative drug R&D, facilitating their entry into the medical insurance catalog, and encouraging clinical application [1] - A multi-channel payment system for innovative drugs is being established, which includes regular adjustments to the medical insurance catalog and the introduction of a commercial health insurance catalog for innovative drugs [1][2] - The initiatives aim to enhance the accessibility of innovative drugs by proposing actionable policies across various stages, including listing, hospitalization, payment, and distribution [2] Group 2: Financial Impact - As of the end of May, the expenditure on negotiated drugs under the medical insurance fund reached 4.1 trillion yuan, driving drug sales to exceed 6 trillion yuan [2] - In 2024, the original insurance premium income for commercial health insurance is projected to reach 977.3 billion yuan, reflecting an 8.2% year-on-year growth, indicating a significant funding scale approaching that of resident medical insurance [2] - Despite the growth in commercial health insurance, there remains substantial room for improvement in its coverage and effectiveness compared to the over 95% utilization rate of basic medical insurance [2]